The National Cancer Institute has awarded a three-year, $1.9 million grant to Lucid Inc. of Rochester, N.Y., to evaluate the company’s VivaScope in vivo confocal microscopy technology for the diagnosis of pigmented lesions. The study will involve approximately 600 patients in New York and California. The instrument is a noninvasive skin imaging tool with cellular resolution that may in the future eliminate the need for skin biopsy.